Runcie K - Search Results

1

Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer.

Hawley JE, Obradovic AZ, Dallos MC, Lim EA, Runcie K, Ager CR, McKiernan J, Anderson CB, Decastro GJ, Weintraub J, Virk R, Lowy I, Hu J, Chaimowitz MG, Guo XV, Zhang Y, Haffner MC, Worley J, Stein MN, Califano A, Drake CG. Hawley JE, et al. Among authors: runcie k. Cancer Cell. 2023 Nov 13;41(11):1972-1988.e5. doi: 10.1016/j.ccell.2023.10.006. Epub 2023 Nov 2. Cancer Cell. 2023. PMID: 37922910 Free article.

2

Prostate Cancer Immunotherapy-Finally in From the Cold?

Runcie KD, Dallos MC. Runcie KD, et al. Curr Oncol Rep. 2021 Jun 14;23(8):88. doi: 10.1007/s11912-021-01084-0. Curr Oncol Rep. 2021. PMID: 34125308 Review.

3

Systemic Treatment for Advanced and Metastatic Non-Clear Cell Renal Cell Carcinoma: Examining Modern Therapeutic Strategies for a Notoriously Challenging Malignancy.

Drobner J, Portal D, Runcie K, Yang Y, Singer EA. Drobner J, et al. Among authors: runcie k. J Kidney Cancer VHL. 2023 Sep 26;10(3):37-60. doi: 10.15586/jkcvhl.v10i3.295. eCollection 2023. J Kidney Cancer VHL. 2023. PMID: 37789902 Free PMC article. Review.

4

Management of Oligometastatic and Locally Recurrent Urothelial Carcinoma.

Liu MA, Li JW, Runcie K. Liu MA, et al. Among authors: runcie k. Curr Oncol Rep. 2024 May;26(5):496-503. doi: 10.1007/s11912-024-01523-8. Epub 2024 Apr 11. Curr Oncol Rep. 2024. PMID: 38602581 Review.

5

State of the Art: Multidisciplinary Management of Oligometastatic Renal Cell Carcinoma.

Dason S, Lacuna K, Hannan R, Singer EA, Runcie K. Dason S, et al. Among authors: runcie k. Am Soc Clin Oncol Educ Book. 2023 May;43:e390038. doi: 10.1200/EDBK_390038. Am Soc Clin Oncol Educ Book. 2023. PMID: 37253211 Free article. Review.

6

Two is company, is three a crowd? Triplet therapy, novel molecular targets, and updates on the management of advanced renal cell carcinoma.

Goodstein T, Yang Y, Runcie K, Srinivasan R, Singer EA. Goodstein T, et al. Among authors: runcie k. Curr Opin Oncol. 2023 May 1;35(3):206-217. doi: 10.1097/CCO.0000000000000939. Curr Opin Oncol. 2023. PMID: 37226958 Free PMC article. Review.

7

Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics.

Runcie K, Budman DR, John V, Seetharamu N. Runcie K, et al. Mol Med. 2018 Sep 24;24(1):50. doi: 10.1186/s10020-018-0051-4. Mol Med. 2018. PMID: 30249178 Free PMC article. Review.

8

Novel Induction Regimens in Multiple Myeloma.

Runcie KD, Mark TM. Runcie KD, et al. Curr Hematol Malig Rep. 2015 Dec;10(4):388-94. doi: 10.1007/s11899-015-0282-1. Curr Hematol Malig Rep. 2015. PMID: 26275667 Review.

9

The in situ oxidation-Wittig reaction of alpha-hydroxyketones.

Runcie KA, Taylor RJ. Runcie KA, et al. Chem Commun (Camb). 2002 May 7;(9):974-5. doi: 10.1039/b201513g. Chem Commun (Camb). 2002. PMID: 12123075

10

Synthesis and profile of SCH351591, a novel PDE4 inhibitor.

Billah M, Cooper N, Cuss F, Davenport RJ, Dyke HJ, Egan R, Ganguly A, Gowers L, Hannah DR, Haughan AF, Kendall HJ, Lowe C, Minnicozzi M, Montana JG, Naylor R, Oxford J, Peake JC, Piwinski JJ, Runcie KA, Sabin V, Sharpe A, Shih NY, Warneck JB. Billah M, et al. Among authors: runcie ka. Bioorg Med Chem Lett. 2002 Jun 17;12(12):1621-3. doi: 10.1016/s0960-894x(02)00225-1. Bioorg Med Chem Lett. 2002. PMID: 12039576

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

16 results

Search Page